American Academy of Value Based Care

Medicare STAR RAS Antagonists Adherence

Quick Reference Guide

2025

Medicare Star RAS Antagonists Adherence Quick Reference Guide

Table of Contents

MEASURE SNAPSHOT ... **3**
PDC CALCULATION ... **4**
Formula ... 4
Calculation Rules (Non-Negotiable) ... 4
Covered Medications (Medicare Part D 2025 RAS Antagonist Class) ... 4
CRITICAL BARRIERS & EVIDENCE-BASED SOLUTIONS ... **5**
Primary Adherence Barriers ... 5
Disparity Gaps Requiring Targeted Action ... 5
HIGH-YIELD INTERVENTIONS ... **5**
Week 1 Quick Wins ... 5
30-Day Impact Strategies Clinical and Economic Outcomes of Adherence ... 6
WORKFLOW OPTIMIZATION ... **7**
A. Clinical Workflow Optimization ... 7
B. Pharmacy Engagement Strategies ... 7
C. Patient Education & Engagement ... 7
D. Simplification of Medication Regimens ... 7
E. Use of Technology & Reminders ... 8
Risk Stratification Protocol ... 8
Outreach Script That Works ... 8
COMPREHENSIVE DOCUMENTATION ... **8**
Must-Have Elements ... 9
Documentation Examples ... 9
Clinical Documentation Optimization ... 9
PERFORMANCE MANAGEMENT ... **9**
Daily Monitor List- Frontline Focus ... 10
Weekly Dashboard Metrics ... 10
Monthly STAR Projections ... 10
FINANCIAL MODELING ... **11**
Investment Requirements (per 1,000 members) ... 11
Real-world example scenario ... 11
REGULATORY REQUIREMENTS ... **11**
Comprehensive Documentation ... 12
A. Measurement Integrity and Stewardship ... 12
2025-2026 Changes to Monitor ... 12
Implications for RAS Adherence Programs ... 12
KEY TAKEAWAYS ... **12**
REFERENCES ... **13**

1. MEASURE SNAPSHOT

CMS Part D Star Measure: D09 - Medication Adherence for Hypertension (RAS antagonists) (MA-H)

Definition: Percentage of **Medicare Part D members aged ≥18 years** who filled prescriptions for a renin–angiotensin system (RAS) antagonist (ACE inhibitors, ARBs, or direct renin inhibitors) to cover **≥80% of days** in the measurement period.[1,2]

Measure Weight: **Triple-weighted (3×)** under Star Ratings; MA **≈30% of total Part D rating**[1, 2]

Exclusions: Members in hospice, palliative care, ESRD, advanced illness/frailty programs, or long-term care facilities, **MAH specific exclusion: prescription for sacubitril/valsartan.**[1, 2]

2025 Financial Impact: **$12.7 billion** in total Quality Bonus Payments (QPBs) across all MA-PD contracts[3]; **$372–$438 per enrollee annually** (depending on plan performance tier)[3]

Star Thresholds:[1-5]

- **Adherent Patient:** PDC ≥80%
- **4-Star Plan:** >80% members adherent (historical 4 Star minimum)
- **5-Star Plan:** >88% members adherent (historical standard)
- Achieving 5 stars requires very high medical adherence(MA), typically requiring that over 90% of its members achieve the ≥ 80% PDC threshold
- 2024 analysis of the **2025 Star Ratings cutpoints** demonstrated high and rising thresholds for MA
  - **MAH (Hypertension): ≥93%**

CMS Cut Points:[1]

Plan Type	1 Star	2 Star	3 Star	4 Star	5 Star
MA-PD	<84%	84% – <88%	88% – <91%	91% – <93%	≥93%
PDP	<88%	88% – <90%	90% – <91%	91% – <93%	≥93%

Current Industry Performance (2024 → 2025 Trend)[1,4,5]

- **National Star Averages:** MA-PD Numeric 89% and Star 3.3, PDP Numeric 89% and Star 2.6
- **62%** of enrollees are in **4+ star contracts**, **down from 79% in 2023**[4]
- **Only 1.8%** of members are in **5-star contracts**, reflecting increased adherence variability and plan stratification risk[4]

Financial Stakes by Rating

Star Rating	Benchmark Bonus	Rebate	Marketing Rights
5 stars	5% increase + QBP	70%	Year-round enrollment
4.5 stars	5% increase + QBP	70%	Standard windows

4 stars	5% increase + eligible for QBP	65%	Standard windows
<4 stars	None	50-65%	Limited

2. PDC CALCULATION

Formula

$$PDC = \frac{Total\ days\ with\ medication\ available}{Days\ in\ measurement\ period} \times 100$$

Success Threshold: ≥80% PDC

Calculation Rules (Non-Negotiable)[6,7]

	Specification (2025 CMS/PQA Standard)	Operational Note
Measurement Start Date	Date of first RAS antagonist fill ≥91 days before December 31	Ensures sufficient observation window for annual PDC
Member Eligibility	Becomes eligible at 2nd fill within measurement year	Confirms chronic use vs trial
Data Source	**Part D Pharmacy claims only** (paid by plan)	Samples, cash-pays, 340B fills excluded
Supply Overlap	Overlapping days shift forward (no double-count)	Avoids inflated PDC (>100% errors)
Hospital or SNF Days	Excluded from denominator if covered stay >7 days	Avoids penalizing temporary non-access
Class Aggregation	ACE + ARB + Direct Renin Inhibitors = one RAS class	Therapy switch counts as continuous adherence
End of Measurement	Dec 31 or disenrollment date (whichever comes first)	Defines final denominator for PDC calculation

Covered Medications (Medicare Part D 2025 RAS Antagonist Class)[8]

1. **Angiotensin-Converting Enzyme (ACE) Inhibitors ("-pril")**
   Benazepril • Captopril • Enalapril • Fosinopril • Lisinopril • Moexipril • Perindopril • Quinapril • Ramipril • Trandolapril
2. **Angiotensin II Receptor Blockers (ARBs) ("-sartan")**
   Azilsartan • Candesartan • Eprosartan • Irbesartan • Losartan • Olmesartan • Telmisartan
3. **Direct Renin Inhibitor**
   Aliskiren (Tekturna) – rarely used in the U.S. Medicare population but included per measure specification.

RAS antagonist class is covered; however, one plan might cover one generic ARB (**Losartan**) at Tier 1, while another plan covers a different generic ARB (**Candesartan**) at Tier 1. Plans should map to measure-recognized NDCs per PQA/CMS.

3. CRITICAL BARRIERS & EVIDENCE-BASED SOLUTIONS

Primary Adherence Barriers[8-12]

	Patient Impact	Evidence-based Intervention
Forgetfulness/Routine disruption	35–40% of non-adherent members	90-day fills + medication synchronization + refill
Cost burden/coverage gap	~1/3 cite affordability issues	$0-copay or tier-reduction programs; MTM cost review; low-income subsidy programs
Adverse effects (ACE cough, hypotension)	10–15% discontinue due to ACE cough	**Switch to ARB** (clinically equivalent outcomes and high rate of symptom resolution)
Therapy complexity/polypharmacy	25% struggle with multi-drug regimens	Single-pill combinations (ACE/ARB + thiazide or CCB)
Access & logistics barriers	15–20% limited pharmacy access	Mail-order or home delivery enrollment

Disparity Gaps Requiring Targeted Action[9-12]

Population Segment	Patient Impact	Interventions
Black and Hispanic beneficiaries	7–10 percentage-point lower adherence even in ≥4-star plans	Community pharmacist partnerships, trust-building outreach, BP self-monitoring support, $0-copay/tier-reduction/subsidy programs; MTM cost review
American Indian/ Alaska Native beneficiaries	lowest adherence rates, with gaps as large as **16%**	Bilingual refill messaging, family-centered education; $0-copay/tier-reduction/subsidy programs; MTM cost review
Southern states (CMS regions 4,6,8,9)	~13% higher non-adherence rates	Mail-order enablement, low-cost generic campaigns
Low-trust index (all groups)	Strongest adherence predictor	Continuity with same prescriber/pharmacy, motivational interviewing, pharmacist follow-up calls

4. HIGH-YIELD INTERVENTIONS

Week 1 Quick Wins[10,13,14]

Action/Strategy	Evidence Summary	Estimated PDC Increase	Operational Cue

Convert to 90-day supplies	Eliminates refill gaps; linked to ≥15% absolute adherence gain	+15 – 20%	Target members ≥2 fills behind schedule
Activate auto-refill & sync	Reduces refill gaps ≈60%;	+25 – 30%	Auto-enroll at the point of sale or MTM call
Enroll in text/app reminders	~10% lower adherence even in ≥4-star plans	+15 – 20%	Use HIPAA-compliant SMS or EHR alert
Generic substitution review	~13% higher non-adherence rates	+20 – 25%	Pharmacist review at every refill

30 Day interventions

Action/Strategy	Target Cohort (How to Select)	Typical 30-day PDC Effect	Implementation Notes
Pharmacist MTM (telephonic/embedded)	Prior gaps, polypharmacy, near-miss cohort	**↑↑ adherence** **↑↑ persistence** ↑↑ on-time refills ↓ gap-days	Use weekly check-ins for high-risk; document barrier, action, outcome(MEAT)
Smart pill bottles /digital monitors	Forgetfulness-flagged, cognitively at-risk, caregivers engaged	**↑ adherence** ↓ late refills ↑ reminders ↓ manual calls	Limit to high-risk decile; pair with SMS/app reminders
Copay assistance /LIS navigation	OOP cost > plan benchmark; prior abandonments; LIS-eligible	**↑–↑↑ adherence via affordability** ↓ abandonment ↑ paid claims ↑ 90-day fills	Build navigator script; close loop with pharmacy on successful enrollment
Mail-order auto-enrollment	Members with travel /transport barriers; stable regimens	**↑–↑↑ adherence via fewer gap opportunities** ↓ gap days ↑↑ on-time refills ↑ delivery success	Offer at refill or MTM; confirm address/stability; align with 90-day supply
90-day supply conversion + refill synchronization	Any member with ≥2 fills and non-complex titration	**↑↑ adherence by reducing refill friction** ↓ Refill freq ↓ Stockouts ↑ PDC ≥80%	Default to 90-day when clinically appropriate; sync all chronic meds
Text/app reminders (HIPAA-compliant)	All non-adherent without cost or clinical barriers	**↑ adherence as an adjunct** ↓ late refills ↑ reminder response	Pair with synchronization /auto-refill; culturally/linguistically tailored messaging

30-Day Impact Strategies Clinical and Economic Outcomes of Adherence[13-16]

Outcome Metric	Improvement in Adherent Cohorts	Mechanism
Blood pressure control	30–45% higher likelihood of achieving target BP	Continuous RAS blockade ↓ angiotensin II → ↓ vasoconstriction & aldosterone → lower BP variability

Major cardiovascular events (MI, stroke, HF)	≈25% relative risk reduction	Sustained BP and vascular remodeling control ↓ end-organ stress & atherothrombotic event
All-cause hospitalization	≈21% reduction (OR 0.79)	Improved BP stability → fewer hypertensive crises, HF decompensations, renal injury
All-cause mortality	≈10–12% relative risk reduction (RR 0.89)	Long-term prevention of CV and renal progression lowers cumulative mortality
Total medical costs	11–20% lower annual cost	Fewer admissions + ER visits + complications → lower PMPY medical cost burden

5. WORKFLOW OPTIMIZATION

Efficient adherence improvement requires coordinated action across clinical teams, pharmacies, and patients. Optimizing workflows directly lifts PDC and Star performance while maintaining audit readiness.

A. Clinical Workflow Optimization

- Embed **PDC dashboards** and auto-alerts for <80% or post-discharge members
- Enable **standing refill protocols** for 90-day or mail-order conversion
- Review **near-miss (PDC 75-79%)** patients in weekly cross-team huddles
- Use a **monthly multidisciplinary review** to close high-risk gaps

B. Pharmacy Engagement Strategies

- Create **preferred pharmacy partnerships** with adherence incentives. Trigger **pharmacist MTM calls** for URGENT/PRIORITY tiers
- Schedule **10–14-day pre-refill outreach** to prevent gaps
- Integrate **community-pharmacy notes** into care-management platforms

C. Patient Education & Engagement

- Apply **brief motivational interview style scripts** that normalize barriers
- Provide **plain-language, bilingual handouts** explaining "PDC ≥80%"
- Link **home BP logs** to refill success to reinforce motivation
- **Celebrate adherence milestones** at each refill contact

D. Simplification of Medication Regimens

- Convert to **fixed-dose combinations** when appropriate (ACE/ARB + thiazide/CCB)
- **Align refill schedules** across chronic conditions
- **Deprescribe duplicates** or low-value meds to cut pill burden
- Prefer **once-daily formulations** for eligible patients

E. Use of Technology & Reminders

- Auto-enroll sub-80% PDC members in **SMS/app reminders**
- Offer **smart caps** or **digital packaging** for forgetfulness/cognitive risk
- Send **portal or IVR confirmations** pre-refill; track completion monthly
- Analyze reminder data to adjust outreach volume

Risk Stratification Protocol

Tier	Improvement in Adherent Cohorts	Response Time	Recommended Actions
URGENT	PDC <40% OR Discharged <7 days OR ≥3 missed fills OR >10 active meds	<24 hours	Pharmacist call; refill + barrier review; coordinate with discharging provider; document MEAT & refill action
PRIORITY	PDC 40–60% OR cost concern OR recent side effect OR new therapy < 90 days	48–72 hours	Outreach for refill sync, copay/LIS check, or ARB switch if ACE cough. Add reminder enrollment
ROUTINE	PDC 60–79% OR stable but suboptimal OR single barrier	Weekly review	Auto-refill setup; 90-day conversion; mail-order or reminder text; monitor PDC ≥80% progress
MAINTENANCE	PDC ≥80% AND no current barriers AND stable >6 months	Monthly	Reinforce adherence success; review at annual wellness or med sync cycle; document continued stability

Re-score all members monthly; automatic escalation if ≥10% PDC drop or hospital discharge event detected.

Outreach Script That Works

"Hi [name], I'm calling from your health plan about your blood-pressure medicine.
I noticed there might be a gap in your refills, and I want to make sure you have what you need.
Many patients tell me [common barrier(s) e.g., 'cost' or 'forgetfulness'] make it tough sometimes.
What's been your experience?"

Follow-up flow:

1. **Listen → validate → summarize barrier**
2. **Offer tailored solutions** (e.g., 90-day supply, mail-order, copay help)
3. **Confirm next refill date + preferred pharmacy**
4. **Document resolution** (date/time, intervention type, new PDC trajectory)

6. COMPREHENSIVE DOCUMENTATION

Accurate, time-stamped documentation is the single most important factor in validating the Star measure during CMS reviews. Every adherence encounter should clearly show the who, what, when, and outcome — structured for traceability and MEAT compliance.[1]

Must-Have Elements

Element	Documentation
Member identifiers	Member ID + full medication name, strength, and dose
Current PDC status	Calculated % with start/end dates of measurement period
Barriers identified	List specific causes (cost, forgetfulness, side effects, access)
Interventions	Each action with an implementation date (e.g., auto-refill, 90-day mail, ARB switch)
Follow-up plan	Defined timeline (e.g., "Next PDC check in 30 days")
Outcome metrics	Post-intervention PDC or refill confirmation noted

Documentation Examples

AUDIT-READY:
"Member #12345, losartan 50mg daily. PDC 42% (1/1-6/30/24).
Barriers: $40 copay, forgets evening dose.
Actions: Enrolled $0 copay program 7/1, switched to AM dosing, 90-day mail order initiated. Next PDC check 8/1."

INSUFFICIENT: "Patient nonadherent to BPmeds. Counseled on importance."

Clinical Documentation Optimization

- Use SOAP or **MEAT** structure for every contact:
  - *Monitor:* current PDC, refill gap, or BP trend
  - *Evaluate:* reason for non-adherence
  - *Assess:* patient readiness, barrier type
  - *Treat/Track:* intervention + timeline
- Auto-populate **PDC fields from claims data** in EHR to reduce error
- Attach **intervention type codes** (e.g., "MTM-1," "MAIL-90," "COPAY-AID") for audit traceability

7. PERFORMANCE MANAGEMENT

Continuous, data-driven monitoring ensures adherence programs stay aligned with CMS cut-points and financial targets. This measure is **100% determined by claims data** (pharmacy fills). There is **no manual chart review** or provider submission that can change the score. If the member didn't fill it, the score drops.

Use daily, weekly, and monthly review tiers to maintain focus and accountability across pharmacy, clinical, and quality teams.[1,3,4]

Daily Monitor List- Frontline Focus

Monitor List	Actionable Criteria	Operational Response
Near-miss members (PDC 75–79%)	Identify via daily PDC feed	Outreach within 48h; refill or mail-order enrollment (eligible for 5–10pt lift)
Recent hospital discharges on RAS	≤7 days post-discharge	Verify med reconciliation + 90-day fill initiation
Upcoming refill windows	Fills due within 10 days	Trigger auto-refill or text reminder
Failed intervention follow-ups	No response within 7 days of outreach	Escalate to pharmacist/care coordinator

Focus on high-yield, high-risk members for rapid action.

Weekly Dashboard Metrics

Metric	Target / Insight	Operational Response
Overall PDC trend	Track plan-level movement toward ≥88% adherence	Escalate cohorts trending <78%
Interventions completed vs pending	Ensure ≥90% follow-through within 5 days.	Redistribute outreach workload
Cost per successful intervention	Target <$50 per member per quarter	Prioritize low-cost, high-yield methods (auto-refill, mail)
Provider-level performance	Identify top and bottom deciles	Targeted feedback, educational resources
Demographic gap analysis	Detect race/region PDC variance >5pts	Deploy equity-focused outreach

Aggregate performance indicators for operational leaders.

Monthly STAR Projections

Indicator	Calculation / Action
Current rate vs CMS cut-points	Compare to latest benchmarks
Members needed to “move the needle”	Estimate count to reach the next Star threshold
Revenue at risk	Project bonus variance per 1,000 members
Resource allocation ROI	Rank interventions by PDC impact per $ spent

Link performance metrics to financial and quality outcomes.

Consistent daily tracking, weekly analytics, and monthly Star projections convert adherence management into predictable financial performance — turning data visibility into sustained Star performance.

8. FINANCIAL MODELING

RAS adherence is one of the highest ROI quality initiatives in Medicare Advantage. Targeted adherence investment consistently yields positive returns for providers and patients. [1-4]

Investment Requirements (per 1,000 members)

Indicator	Calculation/Action	Estimated Annual Cost
Personnel	0.5 FTE Pharmacist ($65K) 1.0 FTE Pharmacy Tech ($35 K) for adherence outreach and monitoring	$100K
Technology	Estimate count to reach the next Star threshold.	$50K
Materials	Project bonus variance per 1,000 members	$10K
Resource allocation ROI	Rank interventions by PDC impact per $ spent	**≈$160K per 1,000 members**

Real-world example scenario

Scenario: A 50,000-member MA-PD plan launched a pharmacist-led adherence program in Q1 2025.

Investment: $8 million (total scaled).

Interventions: 90-day conversion, auto-refill activation, and copay navigation.

Outcomes at 12 months:
- RAS PDC rose from 76% → 87%
- Plan Star rating improved from 3.5 → 4.5
- Annual quality bonus increase ≈ $18 million
- Net ROI ≈ 5.1× within the first year

Operational Insight: The plan retained over 96% of members year-over-year and cut avoidable hospital admissions by ~18%.

A focused RAS adherence initiative can deliver exceptional financial leverage. Meaningful investment in MAH plans typically generates hundreds of thousands in annual returns through reduced medical costs, quality bonus payments, and member retention gains — an ROI approaching **5:1** within the first year.

In real-world Medicare Advantage programs, that translates to **multi-million-dollar quality bonuses and measurable reductions in avoidable hospitalizations**, making RAS adherence one of the **highest-yield investments in the Star Ratings portfolio.**

9. REGULATORY REQUIREMENTS

Comprehensive Documentation

A. Measurement Integrity and Stewardship[1,2,4,17,18]

Ensure the following documentation and system controls are in place for the Adherence to Renin-Angiotensin System (RAS) Antagonists measure:

- **Measurement logic:** Routine validation of PDC calculations to ensure correct inclusion, numerator/denominator alignment, and timely claim capture
- **Data completeness:** Ongoing checks for pharmacy claim feed reliability, including days-covered fields and reconciliation with adherence summaries
- **Care engagement records:** Documentation of outreach and support actions with date, member identifier, barrier addressed, action taken, and outcome
- **Clarification pathway:** Defined process for timely review and resolution of questions related to adherence status or data discrepancies
- **Information stewardship:** Retention of claims, intervention logs, and analytic outputs in accordance with organizational and regulatory standards

2025-2026 Changes to Monitor[1,2,4,17,18]

- The **Health Equity Index (HEI)** or equivalent measure is now a formal part of the Star Ratings framework for measurement year 2025 (impacting the 2027 rating) and will carry increasing weight
- **Cut-points raised** for many Part D adherence and outcome measures in 2026, meaning the bar for "4-star" and "5-star" is higher (by ~3-12 percentage points in some cases)
- **Telehealth interventions** and virtual pharmacist encounters are now explicitly counted as valid "interventions" under outreach/engagement components and should be captured in workflow logs
- Increased CMS focus on **disparity reduction** means plans must stratify adherence by demographics and SDOH (social determinants of health) and document targeted corrective actions

Implications for RAS Adherence Programs

- Given the increased emphasis on equity, your adherence program must track PDC performance by subgroup (e.g., race/ethnicity, LIS status) and document interventions targeted at lower-performing groups
- With higher cut-points, the program needs early-year positioning so that PDC rises into the new elevated benchmarks by measurement year
- Audit logs must clearly distinguish virtual vs in-person interventions, as CMS now treats telehealth outreach as valid
- The algorithm and dashboard must include filters for equity index captures, ensuring plans can report on equity-driven actions and results during reviews

KEY TAKEAWAYS

- **Triple-weighted measure = outsized financial leverage:** RAS adherence drives ~30% of Part D Star performance and directly determines bonus eligibility
- **Binary threshold:** 80% PDC is pass; 79% is fail; every day of coverage matters; aim for >90% PDC
- **ROI powerhouse:** Potential for high return per $ invested, combining quality bonuses, medical cost savings, and retention

- **High-yield action: 90-day fills** and synchronization remain the single most impactful interventions
- **Equity imperative:** Addressing adherence disparities is now **required for 5-Star status** under CMS's Health Equity Index framework
- **Comprehensive Documentation = revenue protection:** Complete documentation trails and validated algorithms determine audit survival
- **Technology accelerates success — but workflow wins:** Platforms enable scale, but human-led pharmacist engagement remains the decisive factor

RAS adherence remains the most profitable, measurable, and controllable driver of Star success. When coupled with equity-focused outreach and airtight documentation, it delivers unmatched ROI, sustained audit compliance, and long-term competitive advantage in the 2026 Part D environment.

REFERENCES

1. Centers for Medicare & Medicaid Services. *2026 Part C & D Star Ratings Technical Notes.* Published September 25, 2025. https://www.cms.gov/files/document/2026-star-ratings-technical-notes.pdf
2. Centers for Medicare & Medicaid Services. *2025 Medicare Advantage and Part D Star Ratings — Fact Sheet.* Published October 10, 2024. https://www.cms.gov/newsroom/fact-sheets/2025-medicare-advantage-and-part-d-star-ratings
3. Cubanski J, Neuman T. *Medicare Advantage Quality Bonus Payments in 2025.* KFF Issue Brief. Published October 2025. https://www.kff.org/medicare/medicare-advantage-quality-bonus-payments/
4. Milliman. *Star Rating Performance Benchmarks and Cut-Points 2025.* Accessed October 26, 2025. https://edge.sitecorecloud.io/millimaninc5660-milliman6442-prod27d5-0001/media/Milliman/PDFs/2024-Articles/11-6-24-Stars-in-Retrograde-Decoding-the-2025-decline.pdf
5. Borrelli EP, Saad P, Barnes N, Lucaci JD. *The influence of medication adherence on Medicare Star Ratings: A decade-long analysis of health plan performance. J Manag Care Spec Pharm.* 2025;31(5):512-519. doi:10.18553/jmcp.2025.31.5.512
6. Johns Hopkins Medicine. *Understanding the Medication Adherence for Hypertension (RAS Antagonists) Measure.* Accessed 2025. https://www.hopkinsmedicine.org/johns-hopkins-health-plans/providers-physicians/health-care-performance-measures/hedis/medication-adherence-hypertension
7. Pharmacy Quality Alliance. *Adherence Measures and Specifications (PDC).* Updated 2025. https://www.pqaalliance.org/adherence-measures
8. Jones DW, Ferdinand KC, Taylor SJ, et al. *2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults. Hypertension.* 2025;82(10):e212-e316. doi:10.1161/HYP.0000000000000249
9. Chang TE, Ritchey MD, Park S, et al. *National rates of nonadherence to antihypertensive medications among insured adults with hypertension, 2015. Hypertension.* 2019;74(6):1324-1332. doi:10.1161/HYPERTENSIONAHA.119.13616
10. Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA. *Nonadherence to antihypertensive drugs: A systematic review and meta-analysis. Medicine (Baltimore).* 2017;96(4):e5641. doi:10.1097/MD.0000000000005641
11. Chen R, Suchard MA, Krumholz HM, et al. *Comparative first-line effectiveness and safety of ACE inhibitors and angiotensin receptor blockers: A multinational cohort study. Hypertension.* 2021;78(3):591-603. doi:10.1161/HYPERTENSIONAHA.120.16667
12. Tsang CC, Browning J, Todor L, et al. *Factors associated with medication nonadherence among Medicare low-income subsidy beneficiaries with diabetes, hypertension, and/or heart failure. J Manag Care Spec Pharm.* 2021;27(8):971-981. doi:10.18553/jmcp.2021.27.8.971

13. Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. *Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open.* 2018;8(1):e016982. doi:10.1136/bmjopen-2017-016982
14. Ruppar TM, Cooper PS, Mehr DR, Delgado JM, Dunbar-Jacob JM. *Medication adherence interventions improve heart failure mortality and readmission rates: Systematic review and meta-analysis of controlled trials. J Am Heart Assoc.* 2016;5(6):e002606. doi:10.1161/JAHA.115.002606
15. Jacob V, Reynolds JA, Chattopadhyay SK, et al. *Pharmacist interventions for medication adherence: Community Guide economic reviews for cardiovascular disease. Am J Prev Med.* 2022;62(3):e202-e222. doi:10.1016/j.amepre.2021.08.021
16. Marcum ZA, Jiang S, Bacci JL, Ruppar TM. *Pharmacist-led interventions to improve medication adherence in older adults: A meta-analysis. J Am Geriatr Soc.* 2021;69(11):3301-3311. doi:10.1111/jgs.17373
17. Centers for Medicare & Medicaid Services. *Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (PACE); Health Equity Index Updates. Federal Register.* 2025;90(73):25781-25964. Published April 15, 2025. Accessed 2025. https://www.federalregister.gov/documents/2025/04/15/2025-06008/medicare-and-medicaid-programs-contract-year-2026-policy-and-technical-changes-to-the-medicare
18. MedicareGuide.com. *2026 Medicare Advantage Star Ratings Changes: How They Impact Plans and Members.* Published May 2025. Accessed 2025. https://medicareguide.com/2026-medicare-advantage-star-ratings-changes

Medical Disclaimer

The information provided by the American Academy of Value-Based Care (AAVBC) in this document, including but not limited to Star Measure guidance, and related content, is intended for educational and informational purposes only. This content is designed to assist healthcare providers, organizations, and professionals in understanding and applying Value-Based Care principles, practices, and regulatory compliance standards.

AAVBC does not provide legal, clinical, or medical advice. The content presented should not be interpreted or relied upon as specific legal, medical, clinical, or professional guidance. While efforts are made to ensure the accuracy and currency of the information provided, AAVBC does not guarantee that the materials presented are complete, comprehensive, or without error.

Providers and healthcare professionals must independently evaluate all content and guidance presented herein in the context of applicable laws, regulations, clinical guidelines, payer policies, patient-specific conditions, and contraindications. Any treatments, procedures, diagnostic approaches, medications, or strategies discussed are illustrative and should not be directly applied without a thorough and independent review of current, evidence-based clinical resources, and regulatory requirements.

For coding, documentation, utilization management, quality measures (including STAR ratings), and compliance matters, users are responsible for consulting official guidelines issued by regulatory bodies, including but not limited to the Centers for Medicare & Medicaid Services (CMS), the American Medical Association (AMA), relevant state agencies, and other authoritative entities.

AAVBC expressly disclaims liability for any loss, claim, or damages arising directly or indirectly from the use or reliance on information provided in this document. Users should consult their organization's legal counsel, compliance officer, or qualified professional advisor for advice specific to their situation.

By accessing and using this document, you agree to AAVBC's terms and acknowledge that the use of the content is at your own risk and discretion.